Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Asset Writedowns and Impairment (2016)

Amphastar Pharmaceuticals has reported Asset Writedowns and Impairment over the past 4 years, most recently at $114000.0 for Q2 2016.

  • Quarterly results put Asset Writedowns and Impairment at $114000.0 for Q2 2016, changed N/A from a year ago — trailing twelve months through Dec 2023 was $114000.0 (changed N/A YoY), and the annual figure for FY2023 was $2.7 million, changed.
  • Asset Writedowns and Impairment for Q2 2016 was $114000.0 at Amphastar Pharmaceuticals, down from $217000.0 in the prior quarter.
  • Over the last five years, Asset Writedowns and Impairment for AMPH hit a ceiling of $217000.0 in Q1 2016 and a floor of $4000.0 in Q3 2015.
  • Median Asset Writedowns and Impairment over the past 4 years was $120000.0 (2013), compared with a mean of $113555.6.
  • Peak annual rise in Asset Writedowns and Impairment hit 64.1% in 2015, while the deepest fall reached 69.23% in 2015.
  • Amphastar Pharmaceuticals' Asset Writedowns and Impairment stood at $120000.0 in 2013, then plummeted by 35.0% to $78000.0 in 2014, then skyrocketed by 64.1% to $128000.0 in 2015, then fell by 10.94% to $114000.0 in 2016.
  • The last three reported values for Asset Writedowns and Impairment were $114000.0 (Q2 2016), $217000.0 (Q1 2016), and $128000.0 (Q4 2015) per Business Quant data.